May 14th 2024
The duration of neoadjuvant chemotherapy may be optimized via MRI guidance for the treatment of hormone receptor-negative/HER2-positive breast cancer.
Patient, Provider and Caregiver Connection™: Addressing Patient Concerns During the Treatment and Management of HR+/HER2- Breast Cancer
View More
Patient, Provider, and Caregiver Connection: Addressing Pediatric and AYA Patient Concerns While Managing Hodgkin Lymphoma
View More
Oncology Consultations®: Next Generation SERDs—Key Data and Practical Takeaways for the Community Physician
View More
Multidisciplinary Management of TNBC: Immunotherapy, PARP, TROP2, Oh My!
View More
Medical Crossfire®: Leveraging Multidisciplinary Teams in Early–Stage Breast Cancer When the Goal is Cure
View More
23rd Annual International Congress on the Future of Breast Cancer® East
July 19-20, 2024
Register Now!
Community Practice Connections™: 14th Annual International Symposium on Ovarian Cancer and Other Gynecologic Malignancies
View More
Community Practice Connections™: The Advent of TROP2-Targeted Treatment Approaches in HR+/HER2- Breast Cancer
View More
Community Practice Connections™: Controversies and Conversations About HER2- Expressing Breast Cancer…Advances in Management of HER2-Low to -Positive Disease
View More
Show Me the Data™: Do We Have Sea Change for Novel Approaches in HR+/HER2- Breast Cancer? CDK, PI3K/AKT, ADC, and Next-Gen SERD Strategies Assessed
View More
Cancer Summaries and Commentaries™: Clinical Updates from Chicago in Breast Cancer
View More
8th Annual School of Nursing Oncology™
August 10, 2024
Register Now!
Applying New Evidence in Multiple Myeloma Care from Frontline to R/R Disease
View More
42nd Annual CFS®: Innovative Cancer Therapy for Tomorrow®
November 13-15, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Medical Crossfire®: How Does Recent Evidence on PARP Inhibitors and Combinations Inform Treatment Planning for Prostate Cancer Now and In the Future?
View More
Medical Crossfire®: How Do Clinicians Integrate the Latest Evidence in Treating Ovarian Cancer to Personalize Care?
View More
Medical Crossfire®: Where Are We in the World of ADCs? From HER2 to CEACAM5, TROP2, HER3, CDH6, B7H3, c-MET and Beyond!
View More
Medical Crossfire: How Has Iron Supplementation Altered Treatment Planning for Patients with Cancer-Related Anemia?
View More
42nd Annual Miami Breast Cancer Conference®
March 6 - 9, 2025
Register Now!
The Evolving Tool Box in Advanced HR+/HER2– Breast Cancer: What You Need to Know About Next-Generation SERDs, PI3K/AKT, ADCs, CDK4/6 and Beyond…
View More
Coffee Talk™: Navigating the Impact of HER2/3, TROP2, and PARP from Early Stage to Advanced Breast Cancer Care
View More
Dr. Jagsi on the Adoption of Hypofractionated Radiotherapy for Breast Cancer
June 24th 2014Reshma Jagsi, MD, DPhil, associate professor, Department of Radiation Oncology, University of Michigan Health System, discusses an analysis of the adoption of hypofractionated radiotherapy for early-stage invasive breast cancer.
For Breast Cancer Patients at Known BRCA Risk, a Role for Testing Prior to Surgery
June 17th 2014The majority of women with breast cancer who undergo the recommended genetic testing for BRCA1/2 mutations and test positive prior to undergoing surgery will change their surgical plan to include a more extensive procedure, a new study reports.
Nurses Design Proactive, Patient-Centered Program to Reduce Lymphedema Risk
June 11th 2014A pilot study of an educational and behavioral program conducted by researchers at the New York University College of Nursing has successfully reduced the risk of lymphedema in breast cancer patients who have undergone axillary lymph node dissection or sentinel lymph node biopsy.
Survey Finds More Inquiries to Genetic Counselors, Including From the "Worried-Well"
June 9th 2014A recent survey conducted by the National Society of Genetic Counselors (NSGC) showed a significant increase in patient calls and requests for testing and referrals from healthcare providers in the year following actress Angelina Jolie's announcement of her BRCA mutation status and subsequent double mastectomy.
Dosing Zoledronic Acid Less Often Doesn't Reduce Efficacy
June 3rd 2014Phase III trial results presented at the 2014 ASCO Annual Meeting showed that the dosing frequency of zoledronic acid (Zometa) can be reduced by 67% without compromising effectiveness in women with breast cancer and bone metastases, potentially lowering the risk of serious adverse events.
Key Role for Exemestane in Preventing Breast Cancer Recurrence in Premenopausal Women
June 2nd 2014Adjuvant exemestane reduced the relative risk of developing subsequent invasive cancer in hormone-receptor–positive (HR+) premenopausal women by 28% compared with tamoxifen when both agents were combined with ovarian function suppression (OFS)
Study Finds Survival and Fertility Benefit When Goserelin Augments Breast Cancer Chemo
June 1st 2014A new study presented at the 2014 ASCO Annual Meeting has found that adding goserelin to chemotherapy for women with early-stage hormone receptor (HR)-negative breast cancer helps both to preserve their fertility and to prolong their survival.
Study Explores Racial/Ethnic Disparities in Incidence of Breast Cancer Subtypes
May 16th 2014An analysis of a large, nationwide dataset has revealed that regardless of their socioeconomic status, black women are nearly twice as likely to be diagnosed with triple-negative breast cancer (TNBC) and Asian/Pacific Islander women are more likely to be diagnosed with HER2-overexpressing breast cancer compared with white women.
Web-Based Program Helps Patients and Survivors to Manage Sexual Side Effects
May 15th 2014Sexual problems, such as loss of desire, failure to get aroused easily, and vaginal dryness and pain during sexual activity, are prevalent among breast cancer survivors, and they rarely go away without treatment.
Orientation Eases Stress and Helps Breast Cancer Patients Manage Neoadjuvant Regimens
May 8th 2014Nurses at the Rutgers Cancer Institute of New Jersey have developed a program to help patients with early-stage breast cancer to better understand and retain information about their presurgical treatments.
Archana Ajmera on Stomatitis Prevention During Metastatic Breast Cancer Treatment
May 3rd 2014Archana Ajmera, RN, MSN, WHNP-BC, ANP-BC, nurse practitioner, University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses stomatitis prevention during everolimus/exemestane treatment for metastatic breast cancer.
Evidence-Based Approaches to Survivorship Care
April 30th 2014The number of cancer survivors in the United States is approaching 14 million, but that good news also means more attention must be paid to quality-of-life concerns for these individuals, as well as any long-term after effects of treatment.
USPSTF, ASCO Issue More Guidance on Genetic Testing Based on Family History
April 24th 2014Oncology practitioners now have several resources to consult for advice on genetic testing for their patients following the US Preventive Services Task Force (USPSTF) December 2013 update of its 2005 BRCA recommendations, plus new recommendations from the American Socieity of Clinical Oncology (ASCO) announced in February and published in the Journal of Clinical Oncology.
Helping Patients to Make Informed Decisions About Fertility Preservation
April 23rd 2014Studies show that young women diagnosed with breast cancer are not routinely receiving information about fertility preservation (FP) before their anticancer therapy begins, posing a missed opportunity for healthcare practitioners to provide women with options for improving their chances for a future pregnancy.
Leslie R. Schover on Vaginal Dryness and Pain in Breast Cancer Patients Treated With AIs
April 17th 2014Leslie R. Schover, PhD, clinical psychiatrist, professor, behavioral science, The University of Texas MD Anderson Cancer Center, discusses vaginal dryness and pain in patients with breast cancer treated with aromatase inhibitors.
Breast Cancer Patients Fare Worse When Adjuvant Chemotherapy Is Delayed
April 14th 2014Breast cancer patients whose chemotherapy is initiated more than 60 days following surgery experience worse survival outcomes, and the impact of treatment delay is greatest among patients with stage III or triple-negative breast cancer and those whose HER2-positive tumors have been treated with trastuzumab
Updated Findings Show Palbociclib Improves PFS, not OS
April 7th 2014Palbociclib, an inhibitor of cyclin-dependent kinases (CDK) 4 and 6, more than doubled progression-free survival (PFS) when used in combination with letrozole for patients with estrogen receptor (ER)-positive, HER2-negative metastatic breast cancer
New Study Shows Fertility Drugs Do Not Increase Breast Cancer Risk, Monitoring Still Warranted
April 3rd 2014Women who took the fertility drugs clomiphene citrate (Clomid) or gonadotropins did not experience an increased risk for breast cancer compared with women who were not treated with those medications, according to a 30-year follow-up study published in the April issue of Cancer Epidemiology, Biomarkers & Prevention.